公开(公告)号：US20240269279A1

公开(公告)日：2024-08-15

申请号：US18569346

申请日：2022-06-14

Applicant: NOVARTIS AG

Inventor： Ivan BOTTOLLI ,  Andreas FISCH

IPC: A61K39/395 ,  A61K9/08 ,  A61K39/00 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  C07K16/42

CPC classification number: A61K39/39566 ,  A61K9/08 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  C07K16/4291 ,  A61K2039/505 ,  C07K2317/94

Abstract: The present invention provides anti-lgE antibodies formulated as stable aqueous pharmaceutical compositions. suitable for injection. An aqueous pharmaceutical composition of the invention includes a sugar (trehalose). a buffering agent (histidine). and a surfactant (polysorbate 20). The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody (at least 50 mg/ml) active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter.